Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Litorina Kapital in connection with acquisition of Björnkläder
Mandate

Vinge advises Litorina Kapital in connection with acquisition of Björnkläder

December 06, 2010

Litorina Kapital has acquired 100 per cent of the shares in Björnkläder AB from Davis Service Group Plc.

Björnkläder is Sweden’s leading specialist supplier of professional workwear and personal protective equipment with nationwide coverage in the Swedish market through its Grolls store network. The company generated approximately SEK 480 million in sales in 2009 and employs approximately 185 people.

Vinge’s team consisted of responsible partner Johan Winnerblad and partner Maria-Pia Hope together with, among others, associates Johan Johansson, Paul Dali and Johan Mattsson. Associate Peter Alstergren provided competition law advice.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024